Does Rallies show 13F holders for ANIX?

Yes. Rallies tracks hedge fund and 13F ownership data for ANIX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ANIX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANIX. It does not provide personalized investment advice.

ANIX (Anixa Biosciences, Inc.) Stock Analysis - Hedge Fund Holdings

Anixa Biosciences, Inc. (ANIX) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIX trades at $2.81 with a market cap of $92.54M and a P/E ratio of -8.04. ANIX moved +3.18% today. Year to date, ANIX is -14.15%; over the trailing twelve months it is +4.60%. Its 52-week range spans $2.07 to $5.46. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces ANIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ANIX stock?

Hedge funds tracked by Rallies that own ANIX include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Anixa Biosciences, Inc..

ANIX Key Metrics

Key financial metrics for ANIX
Metric	Value
Price	$2.81
Market Cap	$92.54M
P/E Ratio	-8.04
EPS	$-0.34
Dividend Yield	0.00%
52-Week High	$5.46
52-Week Low	$2.07
Volume	5
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-11.03M
Gross Margin	0.00%

Top Hedge Funds Holding ANIX

Exoduspoint Capital holds 93.93K shares of ANIX, changed +0.00% as of Dec 31, 2025.

Latest ANIX News

Anixa Biosciences’ CAR-T Patients Survive up to 28 Months in Phase 1 Trial — May 11, 2026
Anixa Biosciences Secures Mexican Patent Extending Vaccine Protection into 2040 — Apr 29, 2026
Anixa to Present Positive Phase 1 Lira-cel Survival Data at ISCT Meeting — Apr 22, 2026
Anixa Biosciences Reports 74% Immune Response and Lira-Cel Survival Data — Apr 9, 2026
Anixa Secures Cytovance Deal After Phase 1 Yields 74% Immune Response — Apr 1, 2026

Recent ANIX Insider Trades

Baskies Arnold M bought 10.00K (~$30.40K) on Jan 28, 2026.
Titterton Lewis H jr bought 10.00K (~$30.80K) on Jul 31, 2025.
KUMAR AMIT bought 5.00K (~$15.80K) on Jul 30, 2025.

ANIX Analyst Consensus

1 analysts cover ANIX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.

Common questions about ANIX

Who owns ANIX stock?: Hedge funds tracked by Rallies that own ANIX include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Anixa Biosciences, Inc..
Does Rallies show 13F holders for ANIX?: Yes. Rallies tracks hedge fund and 13F ownership data for ANIX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ANIX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANIX. It does not provide personalized investment advice.